ArticleProceedings (Baylor University. Medical Center)2026
The utility of genetic testing for pheochromocytoma and paraganglioma.
Article in Proceedings (Baylor University. Medical Center), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPheochromocytoma and paragangliomas are unique neuroendocrine tumors that can be a significant source of morbidity and mortality. It was previously thought that these tumors were largely sporadic. There is a paucity of literature to support routine genetic testing. The aim of this study was to determine the utility of preoperative genetic testing for these tumors.
methodsThis study was a retrospective review of all patients >18 years of age with a diagnosis of a pheochromocytoma or paraganglioma who were evaluated in our surgical oncology clinic from January 1, 2014, through January 1, 2025. Basic demographic data, along with genetic testing, recurrence, and final pathology findings, were collected.
resultsA total of 48 patients were reviewed, with 21 patients completing genetic testing. Fourteen patients (66.6%) were found to have negative genetic testing, while 7 patients (33.3%) had positive genetic testing. There was no difference in age, race, or sex of the patients with positive and negative genetic testing. There was no difference in recurrence (
conclusionGiven the high rate of genetic mutations found in this study, we recommend that all patients with pheochromocytomas and paragangliomas undergo genetic testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.